Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published by: GlobalData

Published: Aug. 31, 2011 - 111 Pages

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Asthma Therapeutics: Introduction

2.1 Disease Overview

2.1.1 Epidemiology

2.1.2 Classic Signs and Symptoms

2.1.3 Etiology

2.1.4 Diagnosis

2.1.5 Classification

2.1.6 Pathogenesis of Asthma

2.1.7 Treatment

2.1.8 Referral Pathway

2.2 GlobalData Pipeline Report Guidance

3 Asthma Therapeutics: Market Characterization

3.1 Asthma Therapeutics Market Size (2005-2010) - Global

3.2 Asthma Therapeutics Market Forecast (2010-2018) - Global

3.3 Asthma Therapeutics Market Size (2005-2010) - The US

3.4 Asthma Therapeutics Market Forecast (2010-2018) - The US Asthma Therapeutics Market Size (2005-2010) - France

3.5 Asthma Therapeutics Market Forecast (2010-2018) - France

3.6 Asthma Therapeutics Market Size (2005-2010) - Germany

3.7 Asthma Therapeutics Market Forecast (2010-2018) - Germany

3.8 Asthma Therapeutics Market Size (2005-2010) - Italy

3.9 Asthma Therapeutics Market Forecast (2010-2018) - Italy

3.10 Asthma Therapeutics Market Size (2005-2010) - Spain

3.11 Asthma Therapeutics Market Forecast (2010-2018) - Spain

3.12 Asthma Therapeutics Market Size (2005-2010) - The UK

3.13 Asthma Therapeutics Market Forecast (2010-2018) - The UK

3.14 Asthma Therapeutics Market Size (2005-2010) - Japan

3.15 Asthma Therapeutics Market Forecast (2010-2018) - Japan

3.16 Drivers and Barriers for the Asthma Therapeutics Market

3.16.1 Drivers for the Asthma Therapeutics Market

3.16.2 Barriers for the Asthma Therapeutics Market

3.17 Opportunity and Unmet Need Analysis

3.18 Key Take away

4 Asthma Therapeutics: Competitive Assessment

4.1 Overview

4.2 Strategic Competitor Assessment

4.3 Marketed Product Profiles

4.3.1 Advair Diskus (fluticasone propionate and salmeterol inhalation powder)

4.3.2 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol)

4.3.3 Singulair (montekeulast sodium)

4.3.4 Foradil (formoterol fumarate inhalation powder)

4.3.5 Accolate (zafirlukast)

4.3.6 Xolair (omalizumab)

4.3.7 Serevent Diskus (salmaterol xinafoate inhalation powder)

4.3.8 Dulera/Zenhale (SCH 418131)

5 Asthma Therapeutics: Pipeline Assessment

5.1 Overview

5.2 Strategic Pipeline Assessment

5.3 Asthma Therapeutics Pipeline - Pipeline by Phases of Development

5.3.1 Asthma Therapeutics - NDA Filed Products

5.3.2 Asthma Therapeutics - Phase III Pipeline

5.3.3 Asthma Therapeutics - Phase II Pipeline

5.3.4 Asthma Therapeutics - Phase I Pipeline

5.3.5 Asthma Therapeutics - Pre-Clinical Pipeline

5.3.6 Asthma Therapeutics - Discovery Pipeline

5.3.7 Technology Trends Analytic Framework

5.4 Asthma Therapeutics -Pipeline by Mechanism of Action

5.5 Asthma Therapeutics - Promising Drugs under Clinical Development

5.6 Molecule Profile for Promising Drugs under Clinical Development

5.6.1 Relovair

5.6.2 CHF 1535 100/6 NEXT DPI or CHF 1535 pMDI

5.6.3 Flutiform (fluticasone proprionate and formoterol fumarate inhalation aerosol)

5.6.4 Reslizumab

5.6.5 VR315

5.6.6 Andolast (CR 2039):

5.6.7 KCA-757/MN-001

5.6.8 Budesonide-Formoterol Formulation

5.6.9 Fluticasone-Salmeterol Formulation

5.7 Key Takeaway

6 Asthma Therapeutics: Clinical Trials Mapping

6.1 Clinical Trials by Region/Country (US, EU5 and Japan)

6.2 Clinical Trials by Phase

6.3 Clinical Trials by Trial Status

6.4 Prominent Sponsors

6.5 Top Companies Participating in Asthma Therapeutics Clinical Trials

7 Strategic Assessment

7.1 Key Events Impacting the Future Market

7.2 Asthma Therapeutics: Implications for Future Market Competition

8 Asthma Therapeutics: Future Players

8.1 Introduction

8.2 Company Profiles

8.2.1 GlaxoSmithKline Plc.

8.2.2 Merck & Co., Inc.

8.2.3 Novartis AG

8.2.4 AstraZeneca

8.2.5 Cephalon, Inc.

8.2.6 Vectura

8.2.7 Orion Corporation

8.2.8 Rottapharma SPA

8.2.9 SkyePharma PLC

9 Asthma Therapeutics: Licensing and Partnership Deals

10 Asthma Therapeutics: Appendix

10.1 Market Definitions

10.2 Abbreviations

10.3 Methodology

10.3.1 Coverage

10.3.2 Secondary Research

10.3.3 Forecasting

10.3.4 Primary Research

10.3.5 Expert Panel Validation

10.4 Contact Us

10.5 Disclaimer

10.6 Bibliography

1.1 List of Tables

Table 1: Asthma Therapeutics Market, Global, Revenue ($bn), 2005-2010

Table 2: Asthma Therapeutics Market, Global, Forecast ($bn), 2010-2018

Table 3: Asthma Therapeutics Market, The US, Revenue ($bn), 2005-2010

Table 4: Asthma Therapeutics Market, The US, Forecast ($bn), 2010-2018

Table 5: Asthma Therapeutics Market, France, Revenue ($m), 2005-2010

Table 6: Asthma Therapeutics Market, France, Forecast ($m), 2010-2018

Table 7: Asthma Therapeutics Market, Germany, Forecast ($m), 2005-2010

Table 8: Asthma Therapeutics Market, Germany, Forecasts ($m), 2010-2018

Table 9: Asthma Therapeutics Market, Italy, Revenue ($m), 2005-2010

Table 10: Asthma Therapeutics Market, Italy, Forecast ($m), 2010-2018

Table 11: Asthma Therapeutics Market, Spain, Revenue ($m), 2005-2010

Table 12: Asthma Therapeutics Market, Spain, Forecast ($m), 2010-2018

Table 13: Asthma Therapeutics Market, The UK, Revenue ($m), 2005-2010

Table 14: Asthma Therapeutics Market, The UK, Forecast ($m), 2010-2018

Table 15: Asthma Therapeutics Market, Japan, Revenue ($m), 2005-2010

Table 16: Asthma Therapeutics Market, Japan, Forecast ($bn), 2010-2018

Table 17: Adverse Reactions With =3% Incidence With Advair Diskus in Adult and Adolescent Patients With Asthma.

Table 18: Pooled Data From Three 12-Week, Double-Blind, Placebo-Controlled Clinical Asthma Trials In Patients 12 Years And Older

Table 19: Adverse Experiences Occurring in =1% of Patients with an Incidence Greater than that in Patients Treated with Placebo

Table 20: Effect of Singulair on Primary and Secondary Endpoints in a Multinational Placebo-Controlled Trial

Table 21: Number And Frequency Of Adverse Experiences In Patients From Multiple-Dose Controlled Clinical Trials

Table 22: Efficacy Results of Study 40 of Foradil

Table 23: Symptom and Rescue Medication Use (Adults with Asthma)

Table 24: A Comparison of Adverse Events Reported by =1% of Zafirlukast-Treated Patients

Table 25: Mean Change from Baseline at Study End Point

Table 26: Adverse Reaction Incidence in Two 12-Week Clinical Trials in Adult and Adolescent Patients With Asthma

Table 27: Study Design of Phase III trial

Table 28: Clinical Trial with Dulera 100 mcg/5 mcg Clinically Judged Deterioration in Asthma or Reduction In Lung Function

Table 29: Clinical Trial With Dulera 200 mcg/5 mcg Clinically Judged Deterioration in Asthma or Reduction in Lung Function

Table 30: Asthma Therapeutics, NDA Filed Products, 2011

Table 31: Asthma Therapeutics, Phase III Pipeline, 2011

Table 32: Asthma Therapeutics, Phase II Pipeline, 2011

Table 33: Asthma Therapeutics, Phase I Pipeline, 2011

Table 34: Asthma Therapeutics, Pre-Clinical Pipeline, 2011

Table 35: Asthma Therapeutics, Discovery Pipeline, 2011

Table 36: Asthma Therapeutics - Most Promising Drugs Under Clinical Development, 2011

Table 37:Study Details of CHF 1535 100/6 NEXT DPI

Table 38: Asthma Therapeutics, Clinical Trials by Country, 2011

Table 39: Asthma Therapeutics - Clinical Trials by Phase, 2011

Table 40: Asthma Therapeutics, Clinical Trials by Status , 2011

Table 41: Asthma Therapeutics, Prominent Sponsors, 2011

Table 42: Asthma Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011

Table 43: GSK - Respiratory and Immuno-inflamation Pipeline Products, 2011

Table 44: GSK -Asthma Pipeline Products, 2011

Table 45: Merck & Co., Inc. - Respiratory Pipeline, 2011

Table 46: Merck & Co., Inc. - Asthma pipeline, 2011

Table 47: Novartis AG - Respiratory pipeline

Table 48: Novartis AG - Asthma Pipeline

Table 49: AstraZeneca - Respiratory Pipeline Products, 2011

Table 50: AstraZeneca - Asthma Pipeline Products, 2011

Table 51: Orion Corporation - Respiratory Pipeline, 2011

Table 52: Orion Corporation - Respiratory Pipeline, 2011

Table 53: Asthma Therapeutics, Global, Deals, 2009-2011

1.2 List of Figures

Figure 1: Asthma Prevalence Control Extrapolated to The European Union Population (in millions)

Figure 2: Asthma Etiology Hypothesis With Common Triggers

Figure 3: Classification of Asthma Control

Figure 4: T lymphocytes in Allergic Asthma

Figure 5: Phases of Asthmatic Attack.

Figure 6: Treatment Of Chronic asthma

Figure 7: Asthma Referral Pathway

Figure 8: Asthma Therapeutics Market, Global, Revenue ($bn), 2005-2010

Figure 9: Asthma Therapeutics Market, Global, Forecast ($bn), 2010-2018

Figure 10: Asthma Therapeutics Market, The US, Revenue ($bn), 2005-2010

Figure 11: Asthma Therapeutics Market, The US, Forecast ($bn), 2010-2018

Figure 12: Asthma Therapeutics Market, France, Revenue ($m), 2005-2010

Figure 13: Asthma Therapeutics Market, France, Forecast ($m), 2010-2018

Figure 14: Asthma Therapeutics Market, Germany, Revenue ($m), 2005-2010

Figure 15: Asthma Therapeutics Market, Germany, Forecast ($m), 2010-2018

Figure 16: Asthma Therapeutics Market, Italy, Revenue ($m), 2005-2010

Figure 17: Asthma Therapeutics Market, Italy, Forecast ($m), 2010-2018

Figure 18: Asthma Therapeutics Market, Spain, Revenue ($m), 2005-2010

Figure 19: Asthma Therapeutics Market, Spain, Forecast ($m), 2010-2018

Figure 20: Asthma Therapeutics Market, The UK, Revenue ($m), 2005-2010

Figure 21: Asthma Therapeutics Market, The UK, Forecast ($m), 2010-2018

Figure 22: Asthma Therapeutics Market, Japan, Revenue ($m), 2005-2010

Figure 23: Asthma Therapeutics Market, Japan, Forecast ($m), 2010-2018

Figure 24: Opportunity and Unmet Need in the Asthma Therapeutics Market, 2010

Figure 25: Asthma Therapeutics, Strategic Competitor Assessment, 2010

Figure 26: Asthma Therapeutics, Molecular Structure of Zenhale

Figure 27: Asthma Therapeutics - Pipeline by Phase of Development, 2011

Figure 28: Asthma Therapeutics, Technology Trends Analytics Framework, 2011

Figure 29: Asthma Therapeutics, Technology Trends Analytics Framework, Description, 2011

Figure 30: Asthma Therapeutics, Pipeline by Mechanism of Action (%), 2011

Figure 31: Asthma Therapeutics, Molecular Structure of Relovair

Figure 32: Asthma Therapeutics, Molecular Structure of Foster

Figure 33: Structure of Andolast

Figure 34: KCA 757/MN001 Structure

Figure 35: Asthma Therapeutics, Clinical Trials by Country, 2011

Figure 36: Asthma Therapeutics, Clinical Trials by Phase (%), 2011

Figure 37: Asthma Therapeutics, Clinical Trials by Status (%), 2011

Figure 38: Asthma Therapeutics, Overall Sponsors (%), 2011

Figure 39: Asthma Therapeutics, Prominent Sponsors (%), 2011

Figure 40: Asthma Therapeutics, Top Companies Participating in Clinical Trials, 2011

Figure 41: Asthma Therapeutics Market, Drivers and Restraints, 2011

Figure 42: Implications for Future Market Competition in the Asthma Market, 2011

Figure 43: Asthma Therapeutics Market, Pipeline by Company, 2011

Figure 44: GlobalData Market Forecasting Model

Abstract

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Asthma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Asthma Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Asthma Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Asthma Therapeutics market

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Asthma Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Asthma Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Asthma Therapeutics market landscape? - Identify, understand and capitalize.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.